imatinib mesylate has been researched along with Lymphocytosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cortes, JE; Hochhaus, A; le Coutre, P; Mohamed, H; Mustjoki, S; Porkka, K; Saglio, G; Schiffer, CA; Shah, NP | 1 |
| Knuutila, S; Lundán, T; Mustjoki, S; Porkka, K | 1 |
2 other study(ies) available for imatinib mesylate and Lymphocytosis
| Article | Year |
|---|---|
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Dasatinib; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Incidence; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Lymphocytosis; Male; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies; T-Lymphocytes, Cytotoxic | 2016 |
Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia.
Topics: Adult; Aged; Benzamides; Bone Marrow; Bone Marrow Cells; Chromosome Banding; Female; Humans; Imatinib Mesylate; Immunophenotyping; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Lymphocytosis; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines | 2007 |